AG-GLICLAZIDE MR 60 MG
GLICLAZIDE : 60 MG · DIN 02483319 · ANGITA PHARMA INC.
Health Canada status: MARKETED
What is AG-GLICLAZIDE MR?
AG-GLICLAZIDE MR 60 MG contains GLICLAZIDE : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02483319, held by ANGITA PHARMA INC., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AG-GLICLAZIDE MR used for?
Control of hyperglycemia in gliclazide responsive diabetes mellitus (stable, mild, non-ketosis prone, maturity onset or adult type) not controlled by diet/exercise or when insulin is inappropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02483319 |
|---|---|
| Brand name | AG-GLICLAZIDE MR |
| Generic / active ingredient | GLICLAZIDE : 60 MG |
| Manufacturer | ANGITA PHARMA INC. |
| Strength | 60 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BB09 GLICLAZIDE |
| AHFS class | 68:20.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Feb-2025 |
| Original market date | 2025-02-03 00:00:00 |
How is it administered?
30 to 120 mg once daily at breakfast. Recommended starting dose is 30 mg daily. Dose adjustments in steps of 30 mg every 2 weeks. Max dose 120 mg/day. Tablets must not be chewed or crushed.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (Section 11 is listed in TOC but content is missing).
How is it supplied?
30 mg: Bottles of 100 and 500; Blisters of 30. 60 mg: Bottles of 100 and 500; Blisters of 30.
Contraindications
Hypersensitivity to gliclazide/sulfonylureas; Type 1 diabetes; diabetic ketoacidosis/coma; stress conditions (infection, trauma, surgery); severe hepatic/renal impairment; miconazole use; pregnancy/lactation.
Warnings and precautions
Risk of severe hypoglycemia; potential for secondary failure; risk of hemolytic anemia in G6PD-deficiency; serious skin reactions (SJS, TEN, DRESS, bullous pemphigoid); contains lactose.
Is GLICLAZIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A10BB09 GLICLAZIDE. 16 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02483300 |
| APO-GLICLAZIDE | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02245247 |
| APO-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02297795 |
| APO-GLICLAZIDE MR | 60 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02407124 |
| DIAMICRON MR | 30 MG | TABLET (EXTENDED-RELEASE) | SERVIER CANADA INC | MARKETED | DIN 02242987 |
| DIAMICRON MR | 60 MG | TABLET (EXTENDED-RELEASE) | SERVIER CANADA INC | MARKETED | DIN 02356422 |
| GLICLAZIDE | 80 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02287072 |
| JAMP GLICLAZIDE-MR | 30 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02429764 |
| JAMP GLICLAZIDE-MR | 60 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02429772 |
| MINT-GLICLAZIDE MR | 30 MG | TABLET (EXTENDED-RELEASE) | MINT PHARMACEUTICALS INC | MARKETED | DIN 02423286 |
Who else supplies GLICLAZIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLICLAZIDE appears in 245 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.